CureMetrix CEO Kevin Harris. File photo by Jamie Scott Lytle

CureMetrix CEO Kevin Harris. File photo by Jamie Scott Lytle

CureMetrix recently got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.

The software, called cmTriage, highlights cases needing urgent attention, replacing first-in, first-out reviews. Ideally, clinicians can review suspicious cases before the patient has left the clinic.

San Diego’s CureMetrix has collected almost 2 million images to build up the detection technology, employing deep learning and artificial intelligence, according to the company.

“Early and accurate detection in breast cancer detection is key in improving cancer survival rates worldwide through the development of next generation medical image analysis solutions,” said CEO Kevin Harris.

The company wants to not only find cancer faster, but cut down on false positives, in a bid to save the health care system money.

How CureMetrix’s system works: The doctor snaps the X-ray and uploads it to a server. The software scans the image for millions of anomalies, isolating the most important and potentially dangerous ones.

On the doctor’s computer, the software places an overlay on the X-ray image, highlighting the concerning anomalies and rating them by severity.

CureMetrix came out of local startup incubator EvoNexus.